Skip to main content
SpringerLink
Log in

Clinician Update: Direct Thrombin Inhibitors in Acute Coronary Syndromes

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Antithrombotic therapy has become the cornerstone of the treatment for atherosclerotic cardiovascular disease. Unfractionated heparin (UFH) has been the thrombin inhibitor of choice for decades. UFH, however, has its deficiencies. To overcome these problems several direct thrombin inhibitors (DTIs) have been developed. These agents are capable of inactivating clot-bound thrombin more efficiently, and provide more predictable and safer anticoagulation in patients with of acute coronary syndromes (ACS). The initial studies of hirudin and bivalirudin in the clinical settings of acute myocardial infarction (AMI), unstable angina (UA) and percutaneous coronary interventions (PCI) conducted in the early 1990s proved to be disappointing. As the knowledge of more appropriate use of these drugs progressed, there is a renewed interest in DTIs. Herein we will review the clinical studies assessing hirudin, bivalirudin and argatroban in the settings of AMI, UA and PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988;77:526-534.

    Google Scholar 

  2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.

    Google Scholar 

  3. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2146.

    Google Scholar 

  4. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Eng J Med 1994;319:1105-1111.

    Google Scholar 

  5. Liaw PC, Becker DL, Stafford AR, et al. Molecular basis for the susceptibility of fibrin-bound thrombin inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-20965.

    Google Scholar 

  6. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S- 275S.

    Google Scholar 

  7. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Eng J Med 1996; 335: 775-782.

    Google Scholar 

  8. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of patient population on the risk of heparin-induced thrombocytopenia. Blood 2000;96:1703-1708.

    Google Scholar 

  9. Berry CN, Girardot C, Lecoffre C, et al. Effects of synthetic thrombin inhibitor argatroban on fibrin-or clotincorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386.

    Google Scholar 

  10. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996;22:185-196.

    Google Scholar 

  11. Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thrombosis and Thrombolysis 2002;13(1):41-47.

    Google Scholar 

  12. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Circulation 1996;94:911-921.

    Google Scholar 

  13. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1994;89:1545- 1556.

    Google Scholar 

  14. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue type plasminogen activator and aspirin in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.

    Google Scholar 

  15. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of TIMI 6 trial. Am J Cardiol 1995;75:7-13.

    Google Scholar 

  16. GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.

    Google Scholar 

  17. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the TIMI 9A trial. Circulation 1994;90:1624-1630.

    Google Scholar 

  18. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-1642.

    Google Scholar 

  19. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34(4):966-973.

    Google Scholar 

  20. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: randomized trial. Lancet 1999;353:429-438.

    Google Scholar 

  21. Antman EA The search for replacement for unfractionated heparin. Circulation 2001;103:2310-2314.

    Google Scholar 

  22. Organization to Assess Strategies for Ischemic Syndromes (OASIS). Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997;96:769-777.

    Google Scholar 

  23. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. HELVETICA Investigators. N Eng J Med 1995;333:757-763.

    Google Scholar 

  24. Rupprecht HJ, Terres W, Ozbek C, et al. Recombinant hirudin (HBW023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995;26(7):1637-1642.

    Google Scholar 

  25. Lindon RM, Theroux P, Lesperance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-1572.

    Google Scholar 

  26. Theroux P, Perez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-2139.

    Google Scholar 

  27. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155- 2161.

    Google Scholar 

  28. White HD and the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358(9296):1855- 1863.

    Google Scholar 

  29. Fuchs J, Cannon CP, for TIMI7 Investigators. Hirulog in the treatment of unstable angina. Results of the TIMI 7 trial. Circulation 1995;92:727-733.

    Google Scholar 

  30. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Eng J Med 1995;333:764-769.

    Google Scholar 

  31. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 1001;142(6):952-990.

    Google Scholar 

  32. Lincoff AM, Kleiman NS, Meierson ES, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143(5):847-853.

    Google Scholar 

  33. Lincoff AM, Bittle JA, Harrington RA, et al. for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 2003; 289(7):853-863.

    Google Scholar 

  34. The EPISTENT Inverstigators. Randomised placebocontrolled and baloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.

    Google Scholar 

  35. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.

    Google Scholar 

  36. Jang IK, Brown DF, Giugliano RP, et al. A multicenter randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 1999;33:1880-1885.

    Google Scholar 

  37. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and anteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb and Throbolysis 2000;10:233-240.

    Google Scholar 

  38. Behar S, Hod H, Kaplinsky E, for the ARGAMI-2 Study Group. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations–ARGAMI-2 study. Circulation 1998;98(Suppl 1):1453-1454.

    Google Scholar 

  39. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.

    Google Scholar 

  40. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparininduced thrombocytopenia. Circulation 2001;103:1838- 1843.

    Google Scholar 

  41. Jang IK, Lewis BE, Matthai WH, et al. Combination of a direct thrombin inhibitor, Argatroban and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. ACC 2002 (submitted abstract)

  42. Shetler TJ, Crowe VG, Bailey BD, et al. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation 1996;94:1719-1725.

    Google Scholar 

  43. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J 2002:143(1):95-105.

  44. Fung AY, Lorch G, Cambier PA, et al. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Am Heart J 1999;138(4 pt 1):696-704.

    Google Scholar 

  45. Klootwijk P, Lenderink T, Meij S, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999;20(15):1101-1111.

    Google Scholar 

  46. Jang IK Direct thrombin Inhibitors in acute coronary syndromes. Lancet 2002;360(9331):491-492 (Correspondence).

  47. Direct thrombin inhibitor trialists' collaborative group.Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Joanna J. Wykrzykowska & Sekar Kathiresan

  2. Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, SA

    Ik-Kyung Jang

Authors
  1. Joanna J. Wykrzykowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sekar Kathiresan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ik-Kyung Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wykrzykowska, J.J., Kathiresan, S. & Jang, IK. Clinician Update: Direct Thrombin Inhibitors in Acute Coronary Syndromes. J Thromb Thrombolysis 15, 47–57 (2003). https://doi.org/10.1023/A:1026144518686

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026144518686

Search

Navigation